Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.03 USD
Change Today +0.02 / 0.50%
Volume 75.1K
IMMU On Other Exchanges
As of 10:06 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

immunomedics inc (IMMU) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - $5.48
52 Week Low
09/17/14 - $3.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUNOMEDICS INC (IMMU)

immunomedics inc (IMMU) Related Bloomberg News

View More Bloomberg News

immunomedics inc (IMMU) Related Businessweek News

No Related Businessweek News Found

immunomedics inc (IMMU) Details

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer. The company’s antibody-drug conjugate (ADC) products comprise IMMU-132, an ADC that contains SN-38, which is in Phase 2 clinical development focusing on triple-negative breast cancer and colorectal cancer; and IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II clinical development for the treatment of metastatic colorectal cancer. Its early-stage products include Veltuzumab, a humanized monoclonal antibody, which is in Phase 2 study; Milatuzumab, an anti-CD74 antibody for the treatment of graft-versus-host disease that has completed initial Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL, which is in Phase 1/2 clinical trial; Milatuzumab-Doxorubicin, a clinically-evaluated agent that is in Phase 1 dose-escalation trial; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone in patients. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has strategic partnership with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

120 Employees
Last Reported Date: 08/25/14
Founded in 1982

immunomedics inc (IMMU) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $618.9K
Founder, Chairman of The Board and Director o...
Total Annual Compensation: $584.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $235.5K
Compensation as of Fiscal Year 2014.

immunomedics inc (IMMU) Key Developments

Immunomedics, Inc. Reports Complete Responses in Patients with Metastatic Triple-Negative Breast Cancer After Sacituzumab Govitecan Treatment

Immunomedics Inc. announced that among 49 patients with metastatic triple-negative breast cancer (TNBC) evaluated for response to treatments with sacituzumab govitecan in a mid-stage clinical study, 31%, or 15 patients, showed a reduction in tumor size of 30% or more. They include 2 patients with complete response. Response assessments were based on the rules set by the Response Evaluation Criteria In Solid Tumors (RECIST 1.1). Adding the 22 patients with responses between less than 30% tumor shrinkage and less than 20% tumor increase, the disease control rate was 76%. Sacituzumab govitecan also produced significant duration of response in these responding patients. Measured as the time it takes from the beginning of sacituzumab govitecan treatments to when the cancer progresses, the median progression-free survival (PFS) for the 48 patients who received the optimal doses of 8 or 10 mg/kg was 6.0 months. Importantly, 63% of patients (22 of 35) had a time-to-progression longer than their last therapy, notwithstanding disease progression has not yet happened in 56% of patients at the time of analysis. A total of 58 patients with relapsed or refractory metastatic TNBC have been enrolled into the multicenter study to receive sacituzumab govitecan once a week for 2 weeks in 21-day cycles. Despite repeated dosing, sacituzumab govitecan was well tolerated by patients. At the optimal doses of 8 and 10 mg/kg, transient neutropenia was the major Grade 3 or 4 adverse events with 26% occurrence. Grade 3 diarrhea was minimal, reported by only 2% of patients.

Immunomedics Inc. Announces Five Presentations at 2015 ASCO Focusing on Antibody-Drug Conjugate Programs

Immunomedics Inc. announced that two of its five abstracts submitted to the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) have been accepted as oral presentations. The two oral presentations will be on the Company's second generation antibody-drug conjugate (ADC) programs for solid cancer therapy. Leading that program is sacituzumab govitecan, an anti-TROP-2 antibody conjugated with SN-38, an active drug from irinotecan. Irinotecan is approved for the treatment of patients with colorectal cancer. Results from a Phase 2 study of sacituzumab govitecan in patients with advanced lung cancer will be updated in one of the 2 oral presentations. In addition to this oral presentation, results with sacituzumab govitecan in patients with late-stage triple-negative breast and gastrointestinal cancers will be reported in a Poster Discussion and a Poster Sessions, respectively. Also presented, in the same Oral Abstract Session as sacituzumab govitecan, will be initial results from a Phase 2 study of labetuzumab govitecan, another SN-38-containing ADC, for patients with metastatic colorectal cancer. The fifth presentation will feature a pilot study on TF2, a bispecific antibody, for pretargeted imaging of breast cancer in a Poster Session.

Immunomedics Inc. Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015

Immunomedics Inc. reported consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company's total revenues were USD 1,182,698 against USD 1,154,341 a year ago. Operating loss was USD 11,125,739 against USD 9,521,874 a year ago. Loss before income tax expense was USD 11,784,823 against USD 9,532,589 a year ago. Net loss attributable to the company’s stockholders was USD 11,756,147 or USD 0.13 per common share against USD 9,505,602 or USD 0.11 per common share a year ago. The increase in net loss of USD 2.3 million was primarily due to the increase in research and development expenses. For the nine months, the company's total revenues were USD 3,257,487 against USD 7,854,612 a year ago. Operating loss was USD 35,031,746 against USD 23,688,244 a year ago. Loss before income tax expense was USD 35,654,380 against USD 23,656,451 a year ago. Net loss attributable to the company’s stockholders was USD 35,601,802 or USD 0.38 per common share against USD 23,579,045 or USD 0.28 per common share a year ago. The USD 4.6 million decrease in total Revenue was primarily resulted from USD 4.3 million lower license fee revenue. The increase in net loss of USD 12.0 million was primarily the result of lower net revenue related to the Algeta agreement, increased research and development costs attributable to clinical trials, and higher legal and professional fees in the current period.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMU:US $4.03 USD +0.02

IMMU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMU.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMMU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 83.0x
Price/Book 69.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at